Retinoic Acids in Cancer Therapy: Mechanisms of Sensitivity, Resistance, and Methods of Delivery (Volume 23) (Cancer Sensitizing Agents for Chemotherapy, Volume 23) - Hardcover

Über die Autorinnen und Autoren

Dr. Ghavami completed his undergraduate training MSc and PhD in clinical biochemistry. He is a cancer biologist and his research focusses on the importance of cross talk of three key cellular stress [apoptosis, autophagy and unfolded protein response (UPR)] in regulation of chemotherapy response in cancer cells including Glioblastoma, Rhabdomyosarcoma and non-small cell lung adenocarcinoma. Dr. Ghavami is currently honorary professor and co-founder of Autophagy Research Centre at Shiraz University of Medical Science and Tehran University of Medical Sciences, honorary professor at Katowice School of Technology, Poland. He is associate editor of BBA-Mol Basis of Disease, Molecular Neurobiology, BB Reports and IJMS.

Ali Zarrabi is an associate professor and principal investigator in the Faculty of Engineering and Natural Sciences, Istinye University, Turkey. Trained as a chemical engineer (BSc and MSc) with a PhD in nanobiotechnology, he leads a research program at the interface of supramolecular chemistry, bioengineering, and nanomedicine to develop smart nano/biomaterials for simultaneous diagnosis and treatment of disease, with a particular focus on nanotheranostics, advanced wound dressings, skin patches, and translational nanomedicine.

Marco Cordani obtained his Ph.D. at the University of Verona, working on the implication of mutated p53 proteins in metabolism and autophagy. Later, he has performed two postdoctoral stays, one at Universidad Autónoma de Madrid (2017) and another at the IMDEA Nanociencia (2018-2020), working on novel nanomedicine and gene editing strategies to counteract cancer. Currently, Postdoctoral Researcher at the University “Claude Bernard” Lyon 1, characterizing the involvement of dependence receptors in cell death and metabolism.

Von der hinteren Coverseite

Retinoic Acids in Cancer Therapy: Mechanisms of Sensitivity, Resistance, and Methods of Delivery provides an overview of how All-Trans Retinoic Acid (ATRA) kills cancer cells and how some cells survive treatment. Focusing on the cellular pathways and compartments involved in ATRA-mediated inhibition of proliferation, this book also discusses how aggressive tumors develop escape routes conferring retinoic acid resistance.

Across 15 chapters, it describes the molecular structure and biological properties of ATRA, explains mechanisms of resistance, and defines ATRA’s efficacy in seven cancer types. It concludes with chapters on ATRA and cancer stem cell biology, strategies to improve treatment, future therapeutic perspectives, and delivery methods to reduce toxicity and enhance anticancer efficacy.

Each chapter includes Learning Objectives and a “What We Learn” section, making the book highly accessible for undergraduate, graduate trainees, scientists, physicians, and biotech companies. Adding simple, attractive schemes and informative tables makes it ideal for all interested in the current status of Retinoic Acids in Cancer Therapy. This book serves as a valuable resource for health professionals, scientists, researchers, clinical practitioners, and all those seeking to broaden their knowledge and develop new drugs or therapeutic strategies to improve ATRA’s efficacy in the treatment of resistant cancers.